Sign up to save your podcasts
Or
Share Breaking News in Pharma and Biotech: Gilead's Yeztugo Approval, Biopharma Deal Premiums, BioNTech-CureVac Merger, and AI in Precision Oncology
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Breaking News in Pharma and Biotech: Gilead's Yeztugo Approval, Biopharma Deal Premiums, BioNTech-CureVac Merger, and AI in Precision Oncology
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Gilead has received approval for a twice-yearly HIV drug, Lenacapavir, which will be marketed as Yeztugo, potentially redefining the prep market. In other news, biopharma deal premiums show intense negotiations, with Sanofi paying a high premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. BioNTech is merging with CureVac after previously criticizing its failed COVID vaccine program. AI is becoming crucial in precision oncology, with companies like AstraZeneca and Pfizer using computational power to design trials and understand challenging cancers better. Intellia Therapeutics aims to transform lives with genome editing treatments.
Support the show
View all episodes
By Pharma and BioTech News
3.5
1414 ratings
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Gilead has received approval for a twice-yearly HIV drug, Lenacapavir, which will be marketed as Yeztugo, potentially redefining the prep market. In other news, biopharma deal premiums show intense negotiations, with Sanofi paying a high premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. BioNTech is merging with CureVac after previously criticizing its failed COVID vaccine program. AI is becoming crucial in precision oncology, with companies like AstraZeneca and Pfizer using computational power to design trials and understand challenging cancers better. Intellia Therapeutics aims to transform lives with genome editing treatments.
Support the show
More shows like Pharma and BioTech Daily
View all
WSJ Your Money Briefing
1,721 Listeners
WSJ What’s News
4,354 Listeners
The McKinsey Podcast
390 Listeners
WSJ Tech News Briefing
1,637 Listeners
HBR IdeaCast
1,831 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
324 Listeners
Becker’s Healthcare Podcast
190 Listeners
Morning Brew Daily
3,000 Listeners
Inside Global Pharma
10 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
The Top Line
15 Listeners
The AI Podcast
6 Listeners